SAN DIEGO, March 6, 2018 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced
that its chief executive officer, Brian
Lian, Ph.D., will deliver corporate presentations at three
upcoming investor conferences.
Details of these presentations are as follows:
- 30th Annual ROTH Conference
Time/Date: 3:00 p.m. PT on Tuesday, March
13, 2018
Location: Ritz-Carlton Laguna Niguel, Dana Point, CA
Room: Blue – Salon 2
- H.C. Wainwright & Co.'s 2nd Annual NASH
Investor Conference
Time/Date: 10:40 p.m. ET on Monday,
March 19, 2018
Location: St. Regis Hotel, New
York
- Oppenheimer's 28th Annual Healthcare
Conference
Time/Date: 2:10 p.m. ET on Tuesday, March
20, 2018 (webcast available)
Location: Westin New York Grand Central Hotel, New York
Room: Track 61
To access the live webcast of Viking's Oppenheimer conference
presentation, please visit "Webcasts & Presentations" within
the News & Events section of Viking's Investors page at
www.vikingtherapeutics.com. Additionally, a replay of the webcast
will be available on the Viking website following the
conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel, first-in-class or
best-in-class therapies for metabolic and endocrine
disorders. The company's research and development activities
leverage its expertise in metabolism to develop innovative
therapeutics designed to improve patients' lives. Viking has
exclusive worldwide rights to a portfolio of five therapeutic
programs in clinical trials or preclinical studies, which are based
on small molecules licensed from Ligand Pharmaceuticals
Incorporated. The company's clinical programs include VK5211,
an orally available, non-steroidal selective androgen receptor
modulator, or SARM, in Phase 2 development for the treatment and
prevention of lean body mass loss in patients who have undergone
hip fracture surgery, VK2809, a small molecule thyroid beta agonist
in Phase 2 development for hypercholesterolemia and non-alcoholic
fatty liver disease, and VK0612, a first-in-class, orally available
drug candidate in Phase 2 development for type 2 diabetes.
Viking is also developing novel and selective agonists of the
thyroid beta receptor for GSD Ia and X-linked adrenoleukodystrophy,
as well as two earlier-stage programs targeting metabolic diseases
and anemia.
Follow Viking on Twitter @Viking_VKTX.
View original
content:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-upcoming-investor-conferences-300608603.html
SOURCE Viking Therapeutics, Inc.